IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

Watson completes acquisition of Actavis for €4.25 billion

2:02 PM MST | November 8, 2012 | Deepti Ramesh

Watson Pharmaceuticals (Parsippany, NJ) says it has completed the previously announced acquisition of generic pharmaceuticals company Actavis (Zug, Switzerland) for €4.25 billion ($5.4 billion). The acquisition creates the world's third-largest generic pharmaceutical company, with anticipated pro forma combined 2012 sales in excess of $8 billion, Watson says. Watson first announced its plans to acquire Actavis last April. The combined company has global and US headquarters at Parsippany, and international headquarters at Zug. Watson says it will adopt...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers

 

 

 













 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2012 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa